Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Short-term Investments (2024 - 2025)

Historic Short-term Investments for BioNexus Gene Lab (BGLC) over the last 2 years, with Q3 2025 value amounting to $1.7 million.

  • BioNexus Gene Lab's Short-term Investments changed N/A to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year change of. This contributed to the annual value of $2.8 million for FY2024, which is N/A changed from last year.
  • BioNexus Gene Lab's Short-term Investments amounted to $1.7 million in Q3 2025.
  • Over the past 5 years, BioNexus Gene Lab's Short-term Investments peaked at $2.8 million during Q4 2024, and registered a low of $1.7 million during Q3 2025.